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Abstract
Background: Previous work has demonstrated immunomodulatory, anti-tumor, anti-metastatic and anti-angiogenic
effects of the small molecule quinoline-3-carboxamide tasquinimod in pre-clinical cancer models. To better understand
the anti-tumor effects of tasquinimod in transplantable tumor models, we have evaluated the impact of the compound
both on recruitment of myeloid cells to tumor tissue and on tumor-induced myeloid cell expansion as these cells are
known to promote tumor development.
Methods: Mice bearing subcutaneous 4 T1 mammary carcinoma tumors were treated with tasquinimod in the drinking
water. A BrdU-based flow cytometry assay was utilized to assess the impact of short-term tasquinimod treatment on
myeloid cell recruitment to tumors. Additionally, long-term treatment was performed to study the anti-tumor effect of
tasquinimod as well as its effects on splenic myeloid cells and their progenitors. Myeloid cell populations were also
immune-depleted by in vivo antibody treatment.
Results: Short-term tasquinimod treatment did not influence the proliferation of splenic Ly6Chi and Ly6Ghi cells, but
instead reduced the influx of Ly6Chi cells to the tumor. Treatment with tasquinimod for various periods of time after
tumor inoculation revealed that the anti-tumor effect of this compound mainly operated during the first few days of
tumor growth. Similar to tasquinimod treatment, antibody-mediated depletion of Ly6Chi cells within that same time
frame, caused reduced tumor growth, thereby confirming a significant role for these cells in tumor development.
Additionally, long-term tasquinimod treatment reduced the splenomegaly and expansion of splenic myeloid cells
during a later phase of tumor development. In this phase, tasquinimod normalized the tumor-induced alterations
in myeloerythroid progenitor cells in the spleen but had only limited impact on the same populations in the
bone marrow.
Conclusions: Our results indicate that tasquinimod treatment reduces tumor growth by operating early after
tumor inoculation and that this effect is at least partially caused by reduced recruitment of Ly6Chi cells to tumor
tissue. Long-term treatment also reduces the number of splenic myeloid cells and myeloerythroid progenitors,
but these effects did not influence established rapidly growing tumors.
Keywords: Tumor growth, Small molecule, Inhibitor, Monocyte, Recruitment
* Correspondence: fredrik.ivars@med.lu.se
Immunology group, Section for Immunology, Department of Experimental
Medical Science, Lund University, Lund, Sweden
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Deronic et al. BMC Cancer  (2016) 16:440 
DOI 10.1186/s12885-016-2481-0
Background
Certain myeloid cell populations are involved in the
pathogenesis of both chronic inflammation and cancer
[1–3]. These myeloid cells are sensitive to environmental
cues and display a high degree of plasticity. Thus, cells
with a similar phenotype can either promote or suppress
immune responses depending on the local microenvir-
onment [4, 5].
To survive and expand, tumors must evade the host’s
immune system [6]. Interestingly, myeloid cells located
within tumor tissue are highly immunosuppressive [7–9],
as a result of various signaling molecules provided by
tumors and stromal cells. The most prominent myeloid
cell populations located in tumors are tumor-associated
macrophages (TAM) and Gr1+ cells. The Gr1+ population
can be subdivided into Ly6Chi monocytes and Ly6Ghi
granulocytes [10]. The Ly6Chi cells can within the tumor
give rise to different populations of TAM [11, 12].
Additionally, Ly6Chi and Ly6Ghi cells present within
tumor tissue are non-proliferative, have a short half-life,
and thus need to be constantly replenished [11, 13–16].
This may, however, not apply to the F4/80hi TAM whose
numbers can also be maintained by local proliferation
[12, 17, 18].
Tumors promote the expansion of myeloid cells by
producing various pro-inflammatory molecules such as
GM-CSF, G-CSF, IL-1β and IL-6 [8, 9, 19, 20]. Depending
on the tumor model used, these cells may expand either
in the bone marrow or the spleen [9]. The expansion in
the spleen creates a myeloid cell reservoir and a source of
Ly6Chi cells that can be recruited into tissues [21, 22]. A
role of this splenic myeloid cell reservoir during tumor
growth was identified, as it was shown that splenecto-
mized mice displayed reduced tumor progression, which
was associated with a decrease in Ly6Chi and Ly6Ghi cells
in the tumor area [14, 23]. In this setting, an increase in
granulocyte-macrophage progenitors (GMP), that were
able to generate the myeloid cells recruited to the tumor,
was identified within the Lin− c-kit+ Sca1− cells in the
spleen [14, 23]. A similar phenomenon was also observed
in other models of inflammatory disease such as athero-
sclerosis and colitis [24, 25].
Quinoline-3-carboxamides (Q compounds) are small
molecule immunomodulators. One such Q compound,
laquinimod, is currently in a phase III cinical trial for
multiple sclerosis (NCT01707992). Another Q compound,
tasquinimod (ABR-215050), has shown proof of concept
in castration-resistant prostate cancer [26, 27]. In pre-
clinical settings, tasquinimod has been shown to potently
reduce the growth of several transplantable mouse and
human xenograft tumors [28–34]. The reduced tumor
growth was, in some of these studies, associated with anti-
angiogenic effects [28, 29, 34]. Further, this compound
was also shown to modulate the function of TAM and
reduce immune suppression [33, 34]. Previous work has
identified S100A9 as a target for the Q compounds, which
prevent S100A9 interaction with its receptors Toll-like re-
ceptor 4 (TLR4) and receptor for glycation end-products
(RAGE) [35]. By binding to these receptors, S100A9, a
well-known alarmin, induces the transcription of various
proinflammatory genes and thus promotes inflammatory
responses [36–38]. S100A9 has, however, also been impli-
cated in tumor development as it was shown to be import-
ant for the accumulation of suppressive myeloid cells and
the negative regulation of the maturation of these cells to
dendritic cells [39–41].
Our previous work demonstrated that the Q compound
paquinimod, which is structurally similar to tasquinimod,
reduced the accumulation of Ly6Chi cells and SiglecF+ eo-
sinophils in a model of sterile acute inflammation [42].
Further, we could show that the ameliorating effect of this
compound in acute EAE, a mouse model for multiple
sclerosis, operated early during the induction phase of the
autoimmune response [43]. In this model, paquinimod
also reduced the immunization-induced splenic myelo-
poiesis. In the current study, we test the hypothesis that
the anti-tumor effects of tasquinimod could in part be
mediated through an impact on alterations in myelo-
poiesis and myeloid cell recruitment to tumors, as these
cells are known to promote tumor growth by their pro-
tumorigenic properties. Herein, we provide evidence in
support of this hypothesis.
Methods
Mice and treatment
Wild type female BALB/c and C57Bl/6 mice were pur-
chased from Taconic Europe (Ry, Denmark). All animal ex-
periments were performed with the permit of the local
committee on the ethics of animal experiments of Malmö
and Lund (permit M12-13). To study the effects of the Q
compound tasquinimod, female mice at the age of 7–10
weeks were treated with tasquinimod dissolved in drinking
water corresponding to a daily dose of about 25 mg/kg
body weight/day. Tasquinimod was provided by Active
Biotech, Lund, Sweden.
Tumor cell lines
The 4 T1 mammary carcinoma and the B16-F10 melanoma
cell lines were initially obtained from ATCC and provided
to us by Active Biotech. The EG7 cell line (OVA-trans-
fected EL4 lymphoma cell line) [44] was obtained from Dr
Clotilde Thery, Institute Curie, INSERM U932, Paris,
France. The cell lines were expanded, frozen in aliquots
and new aliquots regularly used for the in vivo experiments.
The cells were cultured in RPMI medium (RPMI-1640
supplemented with 10 % fetal calf serum, 10 mM HEPES,
1 mM sodium pyruvate, 100 U/ml penicillin-streptomycin
and 50 μM β-mercaptoethanol; all supplements from
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Invitrogen Life Technologies, Paisley, UK) at 37 °C, 5 %
CO2. For trypsinization of 4 T1 cells, trypsin-EDTA
(Sigma-Aldrich, St. Louis, MO) was briefly added to cells
at approx. 80 % confluence and the cells were washed with
RPMI medium.
In vivo tumor growth
Tumor cells were harvested, washed twice in PBS (Invitro-
gen Life Technologies) and resuspended on ice in growth
factor-reduced matrigel (BD Biosceinces, San Jose, CA) at a
concentration of 106 cells/ml. Mice were injected s.c. in the
right flank with 105 cells in 100 μl matrigel and tumors
were allowed to grow for up to 15 days.
In experiments where cell recruitment was studied,
tumor-bearing mice were injected i.p. with a total of
three injections of 2 mg 5-bromo-2’-deoxyuridine (BrdU;
Sigma-Aldrich) starting at day 5 post-inoculation. The
injections were given with 14 h intervals and mice were
sacrificed 14 h following the last injection. In this set-
ting, tasquinimod treatment was started 24 h before the
first BrdU injection and continued until the end of the
study. Seven mice were included in each group.
In experiments where tumor growth was studied,
tasquinimod treatment was started at the day of tumor
cell inoculation and continued either until day 7 post-
inoculation or throughout the study. In some experi-
ments, tasquinimod treatment was started at day 3 or 7
post-inoculation and continued until the end of the study.
Tumors were measured with a caliper every second day
starting on day 6–7 post-inoculation, when tumors were
palpable. The tumor volume was calculated using the
following formula: length x width2 × 0.4. At the end of
each experiment, tumors and spleens were carefully
excised and weighed. Six to ten mice were included in
each group.
Antibody-mediated depletion
Gr1+ or Ly6G+ cells were depleted by i.p. injection of
500 μg anti-Gr1 (clone RB6-8C5) or anti-Ly6G (clone
1A8) antibody (BioXCell, West Lebanon, NH), respect-
ively. Control mice were injected with the equal amount
of an isotype control antibody (clone MPC-11) (BioXCell).
In experiments where tumor growth was studied in con-
junction with cell depletion, tumor cells were inoculated
24 h after antibody injection. Six to seven mice were
included in each group.
Cell preparation
The dissected spleens were mashed in 70 μm cell strainers,
which were washed with Hank’s balanced salt solution
(HBSS) (Invitrogen Life Technologies). Tibias were crushed
in a mortar and the recovered cells washed with HBSS.
Tumors were cut into small pieces with a scalpel and
treated with 2 mg/ml collagenase IV (Worthington,
Lakewood, NJ) and 0.1 % DNase (Sigma-Aldrich) for
40 min at 37 °C. Following the enzymatic treatment,
the pieces were mashed in 70 μm cell strainers. Cells
were quantified using AccuCount beads (Spherotech,
Lake Forest, IL).
Antibodies and flow cytometry
The following antibodies were purchased from Biolegend
(Nordic Biosite, Täby, Sweden): B220-PerCP-Cy5.5
(RA3-6B2), c-kit-APC-Cy7 (2B8), CD3ε-PerCP-Cy5.5
(145-2C11), CD11b-Alexa700 (M1/70), CD11c-APC-
Cy7 (N418), CD16/32-PE (93), CD45.2-PerCP-Cy5.5
(104), CD105-PE-Cy7 (MJ7/18), CD115-APC (AFS98),
CD150-APC (TC15-12 F12.2), F4/80-PE-Cy7 (BM8),
Ly6G-Brilliant Violet 421 (1A8), Sca1-PacificBlue (D7)
and streptavidin-Brilliant Violet 605. The following anti-
bodies were purchased from BD Biosciences: BrdU-FITC,
CD19-PerCP-Cy5.5 (1D3), Ly6C-biotin (AL-21) and
SiglecF-PE (E50-2440). Cells were stained with the above
antibodies in FACS buffer (PBS supplemented with 5 %
fetal calf serum and 0.05 % NaN3 (Sigma-Aldrich)). Fix-
able Viability Dye-eFluor506 purchased from eBioscience
(Nordic Biosite) was used to detect dead cells. For BrdU
staining, the FITC BrdU Flow Kit (BD Biosciences) was
used according to the manufacturer’s protocol. Analysis of
stained cells was performed using the LSRII flow cyt-
ometer (BD Biosciences).
Statistical analyses
All statistical analyses were performed using the Mann–
Whitney U test.
Results
Tasquinimod reduces the recruitment of Ly6Chi cells to
4 T1 tumors
As previous studies had indicated that Q compounds
may influence recruitment of myeloid cells to sites of
inflammation [42, 45, 46], we hypothesized that tas-
quinimod might similarly reduce the recruitment of
pro-tumorigenic myeloid cells to tumor tissue. Tasquini-
mod was also shown to possess anti-angiogenic effects
[28, 29, 34]. We expected that both recruitment of mye-
loid cells to the tumor per se and pro-angiogenic functions
of these cells might be crucial during the early phase of
tumor growth. Therefore, we decided to initially focus our
analyses on the first 7 days of tumor development. Pro-
tumorigenic myeloid cells accumulating within tumors in
part originate from expanded myeloid cell reservoirs in
the spleen [14, 16, 23]. To address our hypothesis, we first
analyzed the accumulation of splenic myeloid cells in mice
inoculated with either B16 melanoma, EL4 lymphoma or
4 T1 mammary carcinoma tumor cells (Fig. 1a), models in
which tasquinimod has shown efficacy on tumor growth
[31, 33, 34].
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There was a statistically significant expansion of splenic
myeloid cells for all three tumor models 7 days after inocu-
lation, but the expansion was most pronounced in 4 T1
tumor-bearing mice, in which Ly6Ghi cells were the
dominant myeloid subpopulation (Fig. 1b). In the
CD11b+ population within the tumor tissue, similarly
to the splenic CD11b+ population, SSChi SiglecF+ eosino-
phils, Ly6Chi monocytes and Ly6Ghi neutrophils were
identified according to the gating strategy in Fig. 1c. A
population characterized as Ly6Clow Ly6Glow was also
detected and approximately one third of these cells were
identified as F4/80+ macrophages. The composition of the
CD11b+ cell population in the 4 T1 tumor is summarized
in Fig. 1d.
Previous studies showed that Ly6Chi and Ly6Ghi
cells do not proliferate within tumors and that these
cells are instead replenished by recruitment from the
periphery [11, 13, 14, 16]. We therefore utilized BrdU
pulse-labeling as a tracker to enable the detection of
recently divided cells that have been newly recruited
to tumor tissue. Based on those previous studies,
Ly6Chi and Ly6Ghi cells present in tumors at the time
of the BrdU pulse would not be expected to incorpor-
ate BrdU.
We administered BrdU by i.p. injections on days 5 and
6 post-4 T1 tumor cell inoculation. To assess the impact
of tasquinimod on cell recruitment, one cohort of these
mice was treated with the compound on days 4 to 7
post-inoculation. Fourteen hours after the final BrdU
pulse, approx. 25 % of the Ly6Chi cells in the tumor were
BrdU-labeled while only a minor fraction of the Ly6Ghi
cells were labeled (Fig. 2a). Similar fractions of these cell
populations were also labeled in the spleen; however,
very few BrdU+ SiglecF+ and F4/80+ cells were detected
in either compartment (Additional file 1: Figure S1A).
Importantly, mice treated with tasquinimod showed a
significantly reduced number of both BrdU+ Ly6Chi cells
(Fig. 2b) and of the total (BrdU+ and BrdU−) Ly6Chi
population (Fig. 2c). In contrast, the treatment neither
affected the number of BrdU+ Ly6Ghi cells (Fig. 2b), nor
the number of total Ly6Ghi cells within tumors (Fig. 2c).
The short-term treatment used here did not affect
the absolute number of BrdU+ Ly6Chi and SiglecF+




























































































Fig. 1 4 T1 mammary carcinoma tumors induce expansion of splenic myeloid cells. C57Bl/6 mice were inoculated with either 105 B16 (n = 6)
or 105 EL4 (n = 7) cells and BALB/c mice were inoculated with 105 4 T1 cells (n = 7) s.c. Naïve C57Bl/6 or BALB/c mice (n = 3) were included as
controls for each tumor type. Spleens and tumors were collected 7 days post-inoculation and analyzed by flow cytometry. a, Frequency of
splenic CD11b+ myeloid cells gated from total viable cells. b, Number of splenic CD11b+, Ly6Chi, Ly6Ghi and SiglecF+ cells in naïve and 4 T1
tumor-bearing mice. c, Gating strategy for the identification of SSChi SiglecF+, Ly6Chi and Ly6Ghi cells within the CD11b+ CD45.2+ cell population in a
4 T1 tumor. d, Pie chart showing the composition of the CD11b+ cell population in a 4 T1 tumor. Representative results of at least two independent
experiments are shown for all experimental settings. *P < 0.05, Mann–Whitney U-test
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splenic populations of these cells (not shown). This
excludes the possibility that the reduction of the
Ly6Chi and SiglecF+ cell populations within tumors
would be due to a reduced splenic reservoir of these
cells. In addition, as the reduction of these populations
is selective for the cells in the tumor, it is unlikely to
be caused by a toxic effect of tasquinimod operating
on the cells themselves.
Taken together, these data indicate that tasquinimod
specifically reduces the recruitment of Ly6Chi cells into
tumors. While we could also detect reduced absolute
number of SiglecF+ cells in tumors of tasquinimod-
treated mice (Fig. 2c), due to the low BrdU incorpor-
ation of these cells (Additional file 1: Figure S1A), we
cannot draw firm conclusions regarding the recruitment
of these cells to tumor tissue.
Tasquinimod reduces tumor growth during the first week
of tumor development
Since tasquinimod treatment reduced the number of
tumor-infiltrating Ly6Chi cells, that have been suggested
to promote tumor growth, angiogenesis and metastasis
[47, 48], we anticipated that short-term exposure to tas-
quinimod, in the early phase of tumor development, may
impact on subsequent tumor growth. Indeed, treatment
only during the first 7 days reduced tumor growth equally
efficiently as treatment throughout the duration of the ex-
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Fig. 2 Tasquinimod reduces the recruitment of Ly6Chi cells to 4 T1 tumors. BALB/c mice were inoculated with 105 4 T1 cells s.c. Tasquinimod
(25 mg/kg/day) was given in the drinking water starting on day 4 post-inoculation and BrdU (2 mg) was injected i.p. starting at day 5 post-inoculation.
Three injections of BrdU were given with regular intervals and the last injection 14 h before sacrifice. Spleens and tumors were collected 7 days
post-inoculation and analyzed by flow cytometry. a, Representative FACS plots showing the efficiency of BrdU labeling of Ly6Chi and Ly6Ghi
cells in a 4 T1 tumor. b, Number of tumor BrdU+ Ly6Chi and BrdU+ Ly6Ghi cells gated from CD11b+ CD45.2+ cells as in Fig. 1c. c, Number of
total tumor Ly6Chi, Ly6Ghi and SiglecF+ cells. d, Number of splenic BrdU+ Ly6Chi, BrdU+ Ly6Ghi and BrdU+ SiglecF+ cells in 4 T1 tumor-bearing
mice. Pooled data (indicated by open and filled symbols, respectively) from two independent experiments are shown (ctrl, n= 14; tasq, n= 14). n.s. = not
significant, ***P< 0.001, Mann–Whitney U-test
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the 4 T1 tumor as similar results were obtained when the
experiments were repeated using the B16 tumor model
(Fig. 3b). These data indicate that the anti-tumor effect of
tasquinimod operates during the early phase of tumor
development.
The effects of tasquinimod on the composition of
myeloid cells in 4 T1 tumors observed at day 7
(Additional file 1: Figure S1B), were lost in mice that
were left untreated until the end of the experiment
at day 14 (Fig. 3c). Mice that were treated throughout all
14 days of tumor growth, however, displayed specifically
reduced frequencies of both Ly6Chi and SiglecF+ cells
within tumors (Fig. 3c). This is in contrast to the B16
tumor model where the frequency of Ly6Chi cells was still
significantly reduced at the end of the study, also when
mice were treated with tasquinimod only during the first
7 days of tumor growth (Additional file 2: Figure S2A).
These cells were thus less efficiently replenished in B16
tumors. This in turn might be a consequence of the





































































































































Fig. 3 The anti-tumor effect of tasquinimod operates during the first week of tumor development. BALB/c and C57Bl/6 mice were inoculated s.c.
with 105 4 T1 and 105 B16 tumor cells, respectively. Tasquinimod (25 mg/kg/day) was given in the drinking water during the indicated time
points. Once palpable, tumors were frequently measured throughout the study and collected at day 14–15 post-inoculation. a, 4 T1 tumor growth
curves (left) and tumor weights at day 14 post-inoculation (right) (ctrl, n = 7; tasq 0–7, n = 7; tasq 0–14, n = 6). b, B16 tumor growth curves (left)
and tumor weights at day 15 post-inoculation (right) (ctrl, n = 6; tasq 0–7, n = 8; tasq 0–15, n = 10). c, Frequency of CD11b+, Ly6Chi, Ly6Ghi and
SiglecF+ cells gated from total viable CD45.2+ or CD11b+ CD45.2+ cells in 4 T1 tumors at day 14 post-inoculation. d, 4 T1 tumor growth curves
(left) and tumor weights at day 15 post-inoculation (right) (ctrl, n = 6; tasq 0–15, n = 6; tasq 3–15, n = 6). Representative results of two independent
experiments are shown for all experimental settings. n.s. = not significant, *P < 0.05, **P < 0.01, Mann–Whitney U-test
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mice (Fig. 1a). Interestingly, the reduced frequency of
Ly6Chi cells in 4 T1 tumors did not result in any add-
itional anti-tumor effect, suggesting that the reduction of
these cells at an early stage of tumor development is suffi-
cient for an effect on tumor growth. As would be expected
from the reduced tumor weight in tasquinimod-treated
mice, the absolute number of CD11b+ cells was also sig-
nificantly reduced (Tasq 0–7 p = 0.0350, Tasq 0–14 p =
0.0152).
To confirm that tasquinimod mainly operates on
tumor growth in the early phase of tumor development,
experiments with 4 T1 and B16 tumors were also per-
formed where treatment with tasquinimod was started
on day 7 post-inoculation and continued until the end of
the study, at day 14. In this setting, tasquinimod failed
to significantly reduce tumor growth in both tumor
models (Additional file 2: Figure S2B). In the 4 T1 tumor
model, there was a similar reduction in frequency of
Ly6Chi cells and SiglecF+ cells within these tumors
(Additional file 2: Figure S2C), as in the experiments
above (Fig. 3c). This would suggest that the effect of tas-
quinimod on these cell populations is not simply due to
a reduced tumor burden. To verify that tasquinimod has
a therapeutic anti-tumor effect, treatment of 4 T1
tumor-bearing mice was instead started on day 3 post-
inoculation and continued until the end of the study, at
day 15. In this setting, tasquinimod indeed displayed a
significant anti-tumor effect (Fig. 3d). Thus, while tas-
quinimod impacts tumor growth during an early stage of
tumor development, the presence of the compound at
the time of tumor inoculation is not essential to induce
a significant anti-tumor effect. Taken together, in the
particular experimental settings used here, these results
indicated that Ly6Chi cells may possess protumorigenic
properties in the early phase of tumor development
while they do not contribute detectably in the late phase.
Antibody-mediated depletion of Ly6Chi cells reduces 4 T1
tumor growth
To verify that Ly6Chi cells play an important role in the
early phase of 4 T1 tumor growth, we depleted these cells
using an anti-Gr1 antibody. As this depletion removes both
Ly6Chi and Ly6Ghi cells [49], another group of mice was se-
lectively depleted of Ly6Ghi cells using an anti-Ly6G anti-
body. The antibodies were injected once, one day prior to
the inoculation of mice with 4 T1 cells. Also, a group of
mice were both injected with anti-Gr1 antibody and treated
with tasquinimod for the first 7 days of tumor growth. As
can be seen in Fig. 4a, one injection of anti-Gr1 antibody
reduced tumor growth with similar efficiency as 7 days of
tasquinimod treatment. Depletion using anti-Ly6G, how-
ever, had no significant impact on tumor growth, confirm-
ing the importance of the Ly6Chi population in promoting
tumor growth in this model. Furthermore, anti-Gr1
antibody combined with tasquinimod treatment for the
first 7 days of tumor growth did not result in any additive
effects (Fig. 4a). This would indicate that the effect of tas-
quinimod on the recruitment of Ly6Chi cells to tumors is a
major anti-tumor mechanism of action of this compound.
To validate the efficiency of the antibody-mediated cell
depletion in this experimental setting, we analyzed mice
1, 3 or 6 days after antibody injection (Additional file 3:
Figure S3A). The anti-Gr1 antibody induced a significant
reduction in numbers of both Ly6Chi and Ly6Ghi cells in
the spleen already 24 h after injection (Fig. 4b). Both cell
populations were still absent at day 3, but repopulated
the spleen at day 6 post-depletion. Injection of anti-
Ly6G antibodies also efficiently depleted the numbers of
splenic Ly6Ghi cells within 24 h but the effect of this
antibody was longer-lasting and the cells were still
absent from the spleen even at day 6 post-depletion
(Fig. 4b). The analyses shown in Fig. 4c, confirm that
both anti-Gr1 and anti-Ly6G treatments strongly re-
duced the appropriate spleen cell populations, rather
than causing down-modulation of epitopes that would
prevent their detection in the FACS analyses. The deple-
tion had similar effects within tumors (Additional file 3:
Figure S3C) and on bone marrow cells, with the exception
that repopulation was more rapid in the bone marrow
(Additional file 3: Figure S3B). Thus, antibody-mediated
depletion of Ly6Chi cells using anti-Gr1 antibody depletes
Gr1+ cells from the spleen for at least up to 3 days and
this is sufficient for a significant anti-tumor effect.
Long-term treatment with tasquinimod influences the
tumor-induced expansion of myeloid cells in the spleen
Since long-term treatment with the Q compounds has
previously demonstrated an impact on inflammation-
induced splenic myelopoiesis [43, 50], we also wanted to
explore this effect further in 4 T1 tumor-bearing mice.
Thus, mice were exposed to long-term treatment with
tasquinimod throughout 14 days of tumor growth. These
mice displayed a significant increase in spleen weight
(Fig. 5a), associated with increased numbers of CD11b+
cells, in particular those co-expressing Ly6G (Fig. 5b). In
contrast, mice treated with tasquinimod throughout the
experiment displayed little splenic enlargement (Fig. 5a)
and reduced frequency (Fig. 5b), as well as absolute num-
ber, of CD11b+ cells in the spleen (Tasq 0–14 p = 0.0012).
Within this population, Ly6Chi cells were significantly re-
duced and there was also a trend towards reduction of
SiglecF+ cells. The Ly6Ghi cells, however, were largely un-
affected (Fig. 5b). When treatment was terminated at day 7
of tumor growth, the effect on Ly6Chi and SiglecF+ cells
was lost, most likely because the spleen had been
replenished with these cells following the termination
of tasquinimod treatment. In summary, while short-
term treatment of tasquinimod did not alter myeloid
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cell populations in the spleen of tumor-bearing mice
(Fig. 2), long-term tasquinimod treatment influenced
the splenic myeloid compartment and reduced the
tumor-induced splenomegaly.
Tasquinimod normalizes the composition of splenic
myeloerythroid progenitor cells in tumor-bearing mice
Tumor-induced accumulation of myeloid cells in the
spleen is at least partially a consequence of extramedullary
myelopoiesis [14, 23]. Considering the effects of long-term
tasquinimod treatment on splenic myeloid cells, we next
evaluated the influence of tasquinimod on hematopoietic
precursors in the spleen. As expected [14], there was an
increased frequency of Lin− c-kit+ Sca1− cells in spleens of
tumor-bearing mice at day 14 post-inoculation as com-
pared to steady-state spleens (Fig. 5c and d). The fre-
quency of this cell population was also increased in the
































































Isotype (day 1) Anti-Gr1 (day 1) Anti-Ly6G (day 1) 
Ly6Ghi
Ly6Chi
Fig. 4 Ly6Chi cells are required for 4 T1 tumor growth. BALB/c mice were inoculated with 105 4 T1 cells s.c. Gr1+ and Ly6G+ cells were depleted
by the i.p. injection of 500 μg anti-Gr1 and anti-Ly6G antibody, respectively, one day prior to the inoculation of 4 T1 cells. Isotype control antibody
500 μg was injected into a control group of mice. Tasquinimod (25 mg/kg/day) was given in the drinking water from the day of inoculation and
throughout the first week of tumor growth. Once palpable, tumors were frequently measured throughout the study and collected at day 14
post-inoculation. a, 4 T1 tumor growth curves (left) and tumor weights at day 14 post-inoculation (right) (ctrl, n = 7; tasq, n = 6; anti-Gr1, n = 7;
anti-Gr1 + tasq, n = 6; anti-Ly6G, n = 7). Representative results of two independent experiments are shown. b, Number of splenic Ly6Chi (left) and Ly6Ghi
(right) cells 1, 3 and 6 days after cell depletion using the indicated antibodies. Pooled data from two independent experiments are shown (n = 4–6 for
all groups). c, Representative FACS plots showing the efficiency of cell depletion in day 1 mice shown in b. n.s. = not significant, *P < 0.05, **P < 0.01,
Mann–Whitney U-test
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tumor-bearing mice, but not in isotype control-treated
tumor-bearing mice (Additional file 4: Figure S4A and
S4B). While tasquinimod did not alter the frequency of
Lin− c-kit+ Sca1− cells, the treatment did increase the fre-
quency of Lin− c-kit+ Sca1+ cells (Fig. 5c and d). Interest-
ingly, the frequency of cells with the same phenotype was
also increased both in the spleen of anti-Gr1-treated mice
(Additional file 4: Figure S4B) and in the bone marrow of
tasquinimod-treated mice (Additional file 5: Figure S5B).
We have not further analyzed the nature of the Lin− c-kit+
Sca1+ cell population.
Although tasquinimod did not influence the total fre-
quency of the Lin− c-kit+ Sca1− population, we wanted
to determine the potential effects of tasquinimod on dis-
tinctive myeloerythroid progenitors within this population.
A study by Pronk et al. previously reported a strategy to de-
fine GMP, as well as pre-GM, pre-MegE (megakaryocyte
erythrocyte progenitors) and pre-CFU-E (erythrocyte pro-
genitors) populations within the Lin− c-kit+ Sca1− cells of
the bone marrow [51]. We similarly identified these cell
populations in the spleen (Fig. 6a and b). Clearly, 4 T1 tu-
mors influenced the composition of the splenic Lin− c-kit+
Sca1− population such that the frequency of Pre MegE and
Pre CFU-E cells were increased at the expense of GMP and
Pre GM cells (Fig. 6b and Additional file 4: Figure S4C).




Fig. 5 Long-term tasquinimod treatment reduces the tumor-induced expansion of splenic myeloid cells. BALB/c mice were inoculated with 105
4 T1 cells s.c. Tasquinimod (25 mg/kg/day) was given in the drinking water during the indicated time points. Spleens were collected 14 days
post-inoculation, weighed and spleen cells analyzed by flow cytometry. a, Spleen weight (left) and representative image of the spleens (right) at
day 14 post-inoculation (naïve, n = 4; ctrl, n = 7; tasq 0–7, n = 7; tasq 0–14, n = 6). b, Frequency of splenic CD11b+, Ly6Chi, Ly6Ghi and SiglecF+ cells
gated from total viable or CD11b+ CD19− cells. c, Representative FACS plots showing the gating of splenic c-kit+ Sca1− and c-kit+ Sca1+ cells within
the Lin− cell population. d, Frequency of splenic c-kit+ Sca1− and c-kit+ Sca1+ cells gated from Lin− cells (naïve, n = 3; ctrl, n = 7; tasq 0–14,
n = 6). Representative results of at least two independent experiments are shown for all experimental settings. n.s. = not significant, *P< 0.05, **P< 0.01,
Mann–Whitney U-test
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have demonstrated the increase of megakaryocytes in the
spleen of 4 T1 tumor-bearing mice as well as a relocaliza-
tion of the erythropoiesis from the bone marrow to the
spleen [52, 53]. Remarkably, tasquinimod completely re-
stored the composition of myeloerythroid precursors within
the Lin− c-kit+ Sca1− cells, in the spleen, to a naïve-like
state (Fig. 6b and Additional file 4: Figure S4C). In terms of
cell number, all analyzed myeloerythroid progenitor popu-
lations were significantly increased in tumor-bearing mice
compared to naïve mice and tasquinimod again specif-
ically reduced numbers of Pre MegE and Pre CFU-E
cells (Fig. 6d).
In the bone marrow, 4 T1 tumors and tasquinimod
treatment induced largely similar effects on CD11b+
cells as in the spleen (Additional file 5: Figure S5A).
While tumor growth resulted in an increased frequency of
Lin− c-kit+ Sca1− cells also in the bone marrow (Additional
file 5: Figure S5B), tasquinimod displayed no impact on the
total frequency of these cells and only a minor impact on
the Pre GM cells within this population (Fig. 6c and
Additional file 5: Figure S5C). Thus, in conclusion, tas-
quinimod restored the composition of myeloerythroid
precursors, which accumulate in the spleen under tumor
burden, to a naïve-like state. However, there was no major
effect on the same populations of cells in the bone marrow,
suggesting that to a certain degree, there is a compart-
mental specificity of tasquinimod.
Discussion
The focus of this study was to investigate the effects of
the Q compound tasquinimod on myeloid cells during
tumor development. In previous reports, we have evaluated
the impact of the Q compound paquinimod on myeloid
cells during complete Freund’s adjuvant (CFA)-induced in-
flammation and could show that the expansion of these
cells in the spleen was reduced [43, 50]. In particular,
Ly6Chi and SiglecF+ cells were affected [43]. In a model of
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Fig. 6 Tasquinimod normalizes the composition of splenic myeloerythroid precursor cells in tumor-bearing mice. BALB/c mice were inoculated with 105
4 T1 cells s.c. Tasquinimod (25 mg/kg/day) was given in the drinking water throughout the study. Spleens were collected 14 days post-inoculation and
analyzed by flow cytometry. a, Gating strategy for the identification of splenic GMP (a), Pre GM (b), Pre MegE (c) and Pre CFU-E (d) cells within
the Lin− c-kit+ Sca1− cell population. b, Pie charts showing the composition of the splenic Lin− c-kit+ Sca1− cell population. c, Pie charts showing the
composition of the bone marrow Lin− c-kit+ Sca1− cell population. Representative results of two independent experiments are shown for a-c. d, Numbers
of splenic myeloerythroid progenitors. Pooled data (indicated by open and filled symbols, respectively) from two independent experiments are shown
(naïve, n= 10; ctrl, n= 14; tasq 0–14, n= 13). n.s. = not significant, **P< 0.01, ****P< 0.0001, Mann–Whitney U-test
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the number of the same cell populations at the inflamma-
tory site. This was not simply a result of compound toxicity,
as it had no effect on these cells during steady-state condi-
tions [42]. Previous work by others has indicated a potential
effect of Q compounds on cell recruitment. One such com-
pound, linomide, was demonstrated to impair leukocyte-
endothelium interactions in a rat model of TNF-α-induced
hepatic injury [45]. Another Q compound, laquinimod, was
suggested to reduce the transmigration of lipopolysacchar-
ide (LPS)-stimulated monocytes in vitro [46]. More re-
cently, paquinimod was also shown to increase the rolling
velocity of leukocytes on inflamed endothelium in vivo [54].
The exact mechanism of action of the Q compounds, and
whether the target cells in our experiments are myeloid
cells or endothelial cells, is still unknown. The human
S100A9 protein was identified as one target molecule of
paquinimod and this compound was shown to inhibit the
binding of S100A9 to both of the pro-inflammatory re-
ceptors TLR4 and RAGE [35]. In a previous study, we
proposed that the S100A9-TLR4 interaction may pro-
mote tumor growth [31], and as discussed therein and
in more recent publications from our group [33, 34],
one mode of action of tasquinimod may be to interfere
with that interaction. Both the myeloid and the endothe-
lial cells could potentially be targets for such blockade, as
they both express TLR4.
Taking these findings into consideration, and the pre-
vious knowledge that Q compounds are able to reduce
the growth of various tumors [28–34], we have here ad-
dressed the impact of tasquinimod on recruitment of
myeloid cells to a transplantable tumor. Further, we have
also investigated its impact on the accumulation of these
cells in the spleen, as the spleen acts as an important
reservoir of myeloid cells during tumor growth in certain
tumor models [14, 16, 23]. The reason why our attention
was turned to myeloid cells was due to the fact that spe-
cific myeloid cell populations, Ly6Chi cells in particular,
have been implicated in promoting tumor development
because of their immunosuppressive and pro-tumorigenic
properties [47, 48].
To analyze cell recruitment to tumors, we used an ap-
proach based on BrdU pulse labeling. It has been dem-
onstrated not only in the 4 T1 tumor model [16], but
also in other spontaneous as well as transplantable
tumor models [11, 13, 14], that Ly6Chi and Ly6Ghi cells
within tumors are in a non-proliferative state and that
their maintenance requires a constant input from external
reservoirs [21]. For this reason, a BrdU pulse of tumor-
bearing mice is likely to result in labeling of these cells only
in peripheral compartments such as the spleen. Indeed, a
previous study that evaluated myeloid cell proliferation in
various organs of 4 T1 tumor-bearing mice, identified the
spleen as the main site for this event [16]. The number of
proliferating myeloid cells in the bone marrow, however,
was very low and for this reason we focused our attention
on BrdU+ cells in the spleen. We show here that short-
term treatment with tasquinimod reduced the number of
BrdU+ Ly6Chi cells in the tumor, but did not affect BrdU+
myeloid cell populations in the spleen. These two ob-
servations, together with the previously published re-
sults [11, 13, 14], led us to conclude that tasquinimod
interferes with recruitment of Ly6Chi cells to the
tumor rather than decreases the number of recruitable
cells. Because of the differential effect of tasquinimod
on Ly6Chi and SiglecF+ cells in the spleen and tumor
in these experiments, we find it unlikely that tasquini-
mod would have a cytotoxic effect on these cells. A
caveat of this approach, however, is that not all myeloid cell
populations incorporate BrdU equally efficiently. Although
a major fraction of Ly6Chi cells and a minor fraction of
Ly6Ghi cells within the tumor were BrdU+ following the
pulse, SiglecF+ eosinophils displayed undetectable levels of
BrdU incorporation. Thus, even though the proportion of
eosinophils was reduced in tumors of the treated mice, we
could not formally address whether the reduction was
caused by reduced recruitment of these cells.
The finding that very few F4/80+ cells within the tumors
had detectable BrdU labeling is somewhat surprising, con-
sidering that previous reports have suggested that Ly6Chi
cells within tumors have the potential to differentiate to
various types of TAM [11]. Furthermore, it has been sug-
gested that differentiated TAM can proliferate [12, 17, 18].
Our data would indicate that the TAM identified in 4 T1
tumors grown for 7 days do not proliferate extensively
and that very few BrdU-labeled Ly6Chi cells differentiate
to TAM within the time frame of the study.
To assess whether tasquinimod-mediated reduction in
tumor-infiltrating Ly6Chi cells could in part underlie its
anti-tumor effects, we decided to temporarily deplete these
cells using a specific antibody. Using this approach, we con-
firmed that these cells promote 4 T1 tumor growth, thereby
indicating that reduction of these cells in tumors is also one
anti-tumor effect of tasquinimod. Additionally, these exper-
iments revealed that the absence of these cells in the spleen,
bone marrow and tumor during the first 3 days of tumor
development was sufficient to reduce tumor growth. Simi-
larly, tasquinimod treatment for 7 days was also sufficient
to reduce tumor growth. However, treatment throughout
all 14 days of tumor growth did not result in an additional
anti-tumor effect despite the fact that the frequency of
Ly6Chi cells within the tumors normalized once the treat-
ment was terminated at day 7. Taken together, these obser-
vations indicate that the anti-tumor effect of tasquinimod is
important during an early phase of tumor development.
In contrast, antibody-mediated depletion of Ly6Ghi cells
did not significantly influence growth of the primary
tumor in our experiments, suggesting that in this tumor
model, these cells may be less important for initiation of
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tumor cell growth than Ly6Chi cells. Further, long-term
treatment of tumor-bearing mice with tasquinimod did
not affect the frequency of splenic Ly6Ghi cells, but re-
duced the frequency of Ly6Chi and SiglecF+ cells. Thus,
tasquinimod treatment targeted the same myeloid cell
populations in tumor and spleen. At present we do not
know whether this observation means that the com-
pound targets a common mechanism or independent
mechanisms at these two sites. We speculate that vas-
cular extravasation of cells in the tumor and retention
of cells in spleen might both involve adhesion to endothe-
lium and that tasquinimod could potentially interfere with
certain cell-endothelial interactions at these two sites.
As previous reports have demonstrated that Ly6Chi
cells contribute to immune suppression, angiogenesis and
metastasis in tumor-bearing mice [47, 48], it seems reason-
able to assume that the reduced recruitment of Ly6Chi cells
during early tumor development results in an environment
less hospitable for tumor growth. Indeed, tasquinimod is
known to affect the tumor microenvironment in several
ways [55]. Thus, tasquinimod possesses anti-angiogenic
properties [28, 29, 34] and, interestingly, the tumor vas-
culature was significantly reduced following 1 week of
treatment [34]. The anti-angiogenic effects of tasquini-
mod correlated with a skewing of the functional pheno-
type of TAM from CD206+ MHCIIlow M2 macrophages
to CD206− MHCIIhi M1 macrophages [33, 34]. It is well
established that M2 macrophages promote angiogenesis
[56, 57]. Recent papers also demonstrated that tasquini-
mod treatment altered the immunosuppressive proper-
ties of CD11b+ cells within tumors [33, 34], which in
turn may be related to the switch from M2 to M1 mac-
rophages. We speculate that the reduced recruitment of
Ly6Chi cells (and potentially of eosinophils) to the
tumor might disrupt the balance between M2 and M1
macrophages. Possibly, the M2 phenotype of TAM can
only be maintained provided that newly arrived Ly6Chi
cells can continuously be polarized to this phenotype
and the M1 macrophages may dominate functionally
once replenishment of the M2 population is reduced.
These factors might impact on the initiation of tumor
cell growth or seeding, resulting in reduced growth of
the tumor itself. Also, when plotting the 4 T1 and B16
tumor growth curves using a logarithmic scale, tasqui-
nimod treatment did not influence the slope of the
growth curves (not shown). This further supports that
the treatment may affect the initiation of tumor cell
growth or seeding rather than tumor cell proliferation
per se. In contrast, tasquinimod treatment started at
day 7, when tumors are well established, did not result
in reduced tumor growth despite a reduced frequency
of Ly6Chi cells within the tumors. It might be argued,
however, that due to the aggressive nature of 4 T1 tu-
mors, treatment started at this stage is futile. When
treatment instead was started at day 3, the anti-tumor
effect of tasquinimod was maintained, indicating that
there is a critical time frame between days 3–7 within
which the anti-tumor effect of tasquinimod is lost.
While 4 T1 tumors in their early phase of development
induced an expansion of myeloid cells in the spleen, there
was no detectable splenomegaly. At a later phase, however,
when tumors were more developed, the spleens were
significantly enlarged and contained increased numbers of
Lin− c-kit+ Sca1− hematopoietic precursor cells. This is
likely the result of an increased production of myelogenic
cytokines by tumor and stromal cells as well as infiltrating
immune cells [8, 47]. Indeed, one previous study showed
that the accumulation of Ly6Ghi cells in 4 T1 tumor-
bearing mice is driven by tumor-produced G-CSF [20].
Recently, it was also demonstrated that G-CSF treatment
could mimic the effects of the 4 T1 tumor on the spleen, as
it induced splenomegaly and an increased erythropoiesis in
this compartment [53]. We detected an increased frequency
of cells with the Lin− c-kit+ Sca1+ phenotype in spleens
from both tasquinimod-treated mice and anti-Gr1-treated
mice, as well as in the bone marrow of tasquinimod-treated
mice. At present we do not know the nature of these
cells, but based on their phenotype, they may contain
hematopoietic precursors [58]. Since both these treat-
ment regimes involve reduction of myeloid cells, we
speculate that the increased frequency of these cells
might be the result of some compensatory mechanism.
We further noted that the numbers of the various
myeloerythroid progenitors that we analyzed in the spleen
were all increased in tumor-bearing mice. In addition, the
composition of the Lin− c-kit+ Sca1− population was al-
tered in these mice, such that the frequencies of Pre MegE
and Pre CFU-E cells increased at the expense of GMP and
Pre GM cells. Tasquinimod treatment restored the com-
position of this cell population to a naïve-like state. This
observation rules out the possibility that the reduction in
the frequency of Ly6Chi and SiglecF+ cells in the spleen
following long-term tasquinimod treatment would be due
to reduction of the number of GMP or Pre GM cells. We
detected similar effects of tasquinimod on splenic myeloid
cells and hematopoietic precursor cell populations when
treatment of tumor-bearing mice was initiated 7 days
post-inoculation, despite the lack of anti-tumor effect.
Thus, the effects of tasquinimod on splenic myeloid cells
and their precursors are not a result of reduced tumor
burden. However, while these effects of the compound on
splenic cells did not reduce the growth of already estab-
lished rapidly growing tumors, it remains possible that
such effects might have an impact on other, more slowly
developing tumors.
In the bone marrow, tumor growth changed the compos-
ition of the Lin− c-kit+ Sca1− population such that GMP
and Pre GM cells were increased at the expense of Pre
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MegE and Pre CFU-E cells. The absolute numbers of these
cell populations, however, were not altered which correlates
with previous findings that have proposed the spleen as the
main site of progenitor cell expansion during 4 T1 tumor
growth [16]. The effects of tasquinimod in this compart-
ment differed from the spleen such that treatment did not
completely normalize the composition of the Lin− c-kit+
Sca-1− population, but rather decreased the frequency of
Pre GM cells. Further studies are required to elucidate the
compartment-specific effects of tasquinimod. Recently, a
subset of F4/80hi VCAM-1+ CD169+ macrophages was
demonstrated to support splenic myelopoiesis as well as
erythropoiesis, similar to what has previously been shown
for the bone marrow [53, 59, 60]. However, tasquinimod
displayed no effect on number or frequency of this particu-
lar subset of macrophages in the spleen. Thus, the effects of
the compound on the myeloerythroid precursors cannot be
explained by an impact on numbers of these cells, but it re-
mains possible that it may impact on their function.
Conclusions
This study shows that tasquinimod impacts myeloid cells
during tumor growth in a dual fashion. Tasquinimod re-
duces the recruitment of pro-tumorigenic Ly6Chi cells
into tumors during an early phase of tumor development
without influencing the proliferation of these cells in the
spleen. At a later phase of tumor development, long-
term tasquinimod treatment reduces the accumulation
of myeloid cells in the spleen and normalizes the com-
position of myeloerythroid progenitors at this site. The
same progenitors in the bone marrow, however, are
much less affected. Whether or not these effects are
somehow connected remains to be assessed.
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